Holistic ALS Neurologist/Neuroscientist @ Johns Hopkins. Director, Target ALS Postmortem Core. Chair, DOD (CDMRP) ALSRP Programmatic Panel. Views are my own.
May 11, 2020 • 10 tweets • 6 min read
@bsw5020 1/ Several independent points. 1. As a "PROGNOSTIC" biomarker, a single baseline measurement can predict rate of decline and survival probability at a given later time-point - enables more reliable detection a treatment effect with a smaller number of patients enrolled.
@bsw5020 2/ Serum to CSF neurofilament concentrations were strong, particularly for NfL on the Simoa platform - so can potentially use a blood test instead of spinal fluid.
